Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-07-21

Schrodinger, Inc.

Schrödinger sells molecular modeling, simulation, and discovery workflow software and also monetizes collaborative and proprietary drug discovery programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From chemistry tool to discovery operating layer

The opportunity is a better, more recurring software business with higher usage capture, not a one-shot drug jackpot. The stock can compound well if AI expands paid discovery throughput before generic agents reduce Schrödinger to a back-end engine.

Analysis

Thesis

Schrödinger can evolve from a lumpy niche license vendor into a higher-quality discovery operating layer: if hosted delivery, programmatic workflows, and Bunsen expand paid throughput inside large pharma, software value capture compounds while collaborations add asset upside without forcing balance-sheet-breaking drug spend.

Last Economy Alignment

AI should increase molecular discovery throughput and raise demand for Schrödinger’s physics and workflow stack, but it must keep control of the workflow layer so general agents do not compress pricing power.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.2x (from 5 most recent analyses)

Reasoning

The upside is mainly a quality-of-revenue and workflow-depth rerating, not a heroic single-asset drug call. If hosted delivery makes revenue more predictable, Bunsen expands paid usage, and large pharma teams keep Schrödinger as the operating layer for discovery work, the market can value it more like durable vertical science software with biotech optionality instead of a noisy mix of licenses and milestones.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The central risk is value capture, not scientific relevance. Schrödinger likely stays useful, but the upside narrows sharply if hosted conversion weakens reported quality, if AI agents own the customer relationship, or if large-account expansion and pipeline partnering do not convert workflow relevance into durable recurring economics.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material SEC or investor-relations disclosure appeared in the last 7-10 days; the thesis is still gated by the same summer product and hosted-conversion milestones.
The summer launch window for Bunsen is now tighter, so the absence of a delay notice modestly supports timing confidence but does not prove demand.
There is still no fresh public readout on hosted mix, software margin recovery, or monetizable Bunsen usage; the next quarterly update remains the key repricing event.

Forecast update

Lower starting expectations and the added Ajax cash strengthen the payoff profile, while the core dependency on workflow ownership is unchanged.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.50

They control valuable scientific software and the workflow where drug teams run and track discovery work, so cheaper AI can increase how much paid work flows through their system. The risk is that a generic AI assistant becomes the front door and Schrödinger gets pushed into the background, where pricing power is weaker.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.57

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research